Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Assets Average (2016 - 2025)

Karyopharm Therapeutics' Assets Average history spans 13 years, with the latest figure at $102.3 million for Q4 2025.

  • For Q4 2025, Assets Average fell 42.17% year-over-year to $102.3 million; the TTM value through Dec 2025 reached $102.3 million, down 42.17%, while the annual FY2025 figure was $136.4 million, 32.61% down from the prior year.
  • Assets Average reached $102.3 million in Q4 2025 per KPTI's latest filing, up from $100.6 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $342.0 million in Q1 2023 to a low of $100.6 million in Q3 2025.
  • Average Assets Average over 5 years is $235.3 million, with a median of $262.8 million recorded in 2021.
  • Peak YoY movement for Assets Average: rose 16.42% in 2023, then tumbled 50.15% in 2025.
  • A 5-year view of Assets Average shows it stood at $279.7 million in 2021, then increased by 5.36% to $294.7 million in 2022, then fell by 13.4% to $255.2 million in 2023, then crashed by 30.66% to $176.9 million in 2024, then tumbled by 42.17% to $102.3 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Assets Average are $102.3 million (Q4 2025), $100.6 million (Q3 2025), and $116.3 million (Q2 2025).